BioNTech SE BNTX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.80B | 3.09B | 3.27B | 3.32B | 3.53B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.80B | 3.09B | 3.27B | 3.32B | 3.53B |
| Cost of Revenue | 654.62M | 722.23M | 696.12M | 700.76M | 607.84M |
| Gross Profit | 2.15B | 2.37B | 2.57B | 2.62B | 2.92B |
| SG&A Expenses | 865.61M | 833.76M | 759.65M | 710.12M | 597.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 510.55M | 1.24B | 987.97M | 952.16M | 785.10M |
| Total Operating Expenses | 4.49B | 5.15B | 4.82B | 4.64B | 4.33B |
| Operating Income | -1.69B | -2.06B | -1.56B | -1.32B | -801.12M |
| Income Before Tax | -1.67B | -1.90B | -1.36B | -1.16B | -575.80M |
| Income Tax Expenses | 47.06M | 66.33M | 92.14M | 103.34M | 57.46M |
| Earnings from Continuing Operations | -1.72K | -1.97K | -1.45K | -1.26K | -633.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.72B | -1.97B | -1.45B | -1.26B | -633.26M |
| EBIT | -1.69B | -2.06B | -1.56B | -1.32B | -801.12M |
| EBITDA | -815.00M | -1.42B | -1.17B | -1.03B | -425.30M |
| EPS Basic | -6.83 | -7.82 | -5.87 | -5.23 | -2.63 |
| Normalized Basic EPS | -3.14 | -4.17 | -3.03 | -2.65 | -1.12 |
| EPS Diluted | -6.84 | -7.82 | -5.87 | -5.23 | -2.63 |
| Normalized Diluted EPS | -3.16 | -4.17 | -3.03 | -2.65 | -1.12 |
| Average Basic Shares Outstanding | 999.94M | 989.79M | 978.08M | 965.14M | 961.42M |
| Average Diluted Shares Outstanding | 1.00B | 989.79M | 978.08M | 965.14M | 961.42M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |